Last update 1/2025

			Novelty				Development Stage								
AMR Accelerator Project	**Asset Owner**	**Programme**	**New Class**	**New MoA**	**Mode of Action (MoA)**	**Description**	**Discovery**	**(Pre)-Hit to Lead**	**Lead to Candidate**	**Candidate to Phase I**	**Phase I**	**Phase 2a - alone or in combi-nation**	**Phase 2b - Dose ranging**	**Phase 2b - Regimen selection**	**Phase 2c - Duration rando-mization**
AB-Direct €4 m	GSK	Gepotidacin tissue distribution	✓	✓	Topoisomerase type II inhibitor	Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.					→				
ERA4TB €208 m		ERA4TB-01	✓	✓	Cholesterol catabolism.	Molecule targeting mycobacterial cholesterol cycle.					→				
		ERA4TB-02	✓	✓	*Mycobacterium tuberculosis* tryptophan synthase	Compound targeting *Mycobacterium tuberculosis* tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.			→						
		ERA4TB-03			Electron chain transport.	Compounds targeting energy metabolism.					→				
		ERA4TB-04	✓	✓	Lysine transfer RNA synthase	Compound targeting lysine transfer RNA synthase (Rv3598c), which is an essential gene as assessed by transposon mutagenesis.			→						
		ERA4TB-06	✓	✓	Mycobacterial membrane protein Large 3 (Mmpl3)	Potent in vitro inhibitory and bactericidal activity against *Mycobacterium tuberculosis.*			→						
		ERA4TB-09	✓	✓	Unknown.	Natural product analogs active against *Mycobacterium tuberculosis.*			→						
		ERA4TB-10	✓	✓	Targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).	Derivative of piperazinobenzothiazinone that acts as an anti-mycobacterial compound.					→				
		ERA4TB-11	✓	✓	Inhibits leucyl tRNA synthetase (LeuRS)	Small molecule oxaborole.					→				
		ERA4TB-13	✓	✓	Cholesterol catabolism.	Targets cholesterol cycle in *Mycobacterium tuberculosis.*				→					
		ERA4TB-14	✓	✓	Inhibits the mycobacterial cytochrome bc1 complex in the cellular respiration pathway.	Small molecule compound that leads to the depletion of ATP in three mycobacterial species, *M. tuberculosis*, *M. leprae*, and *M. ulcerans*					→				
		ERA4TB-15	✓	✓	Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.	A novel class of small-molecule antibiotics shown to inhibit new targets within the *M. tuberculosis* mycolic acid biosynthesis pathway.			→						
		ERA4TB-16	✓	✓	Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.	A novel class of small-molecule antibiotics shown to inhibit new targets within the *M. tuberculosis* mycolic acid biosynthesis pathway.			→						
		ERA4TB-17	✓	✓	Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.	A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.			→						
		ERA4TB-18	✓	✓	Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.	A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.			→						
GNA NOW €21.6 m	GSK	Gepotidacin	✓	✓	Topoisomerase type II inhibitor	Gepotidacin is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site by inhibition of two different Type II topoisomerase enzymes. Thanks to positive PhIII results for other indications (uUTI & gonorrhoea) is investigated by GNA NOW for its suitability to treat severe enteric infections in low- and middle income countries.				→					
RespiriTB €9 m	JANSSEN	BC1 back up	✓	✓	Cytochrome bc1 complex in the cellular respiration pathway.	Lead optimisation program on BC1 inhibitors.			→						
		MenG	✓	✓	Inhibits menG, a product of which catalyses methylation of demethylmenaquinone.	H2L medChem for novel menaquinone biosynthesis inhibitors.		→							
		BDQ LAI	✓		ATPase.	Novel long-acting injectable formulation of bedaquiline for Tb preventive therapy.				→					
		PASA	✓		Dihydrofolate reductase (DHFR).	Novel para-Aminosalicylic acid (PAS) analogues.		→							
		HDT	✓	✓	Various.	Exploring known host-directed therapies for TB treatment.	→								
		Mtr	✓	✓	*Mycobacterium* transcription regulator (Mtr).	Target exploration of *Mycobacterium* transcription regulator (Mtr) complex.	→								
RespiriNTM €8 m	BioVersys AG	BV500			Inhibition of bacterial RNA polymerase.	BV500 program results from BioVersys' proprietary Ansamycin Chemistry platform. The compounds are designed to circumvent intrinsic resistance mechanisms in *M. abscessus*, while maintaining a broad anti-NTM spectrum of activity			→						
TRIC-TB €8.3 m	BioVersys and GSK	Alpibectir	✓	✓	Bacterial transcriptional regulation.	Boosts ethionamide efficacy and lowers the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections.						→*			
UNITE4TB €185 m	GSK	GSK656	✓	✓	Suppresses protein synthesis in *Mycobacterium tuberculosis* by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS).	A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.								→	
	Leibniz-HKI/ LMU	BTZ-043	✓	✓	Inhibits an essential enzyme for cell wall synthesis in *Mycobacterium tuberculosis.*	A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.							→	→	

Accelerating scientific discoveries in the antimicrobial resistance (AMR) field

COMBINE €25 m	Providing learnings derived from shared vaccine and/or antibacterial clinical trial data, and improving understanding of variability and translatability of animal models of bacterial infection.
PrIMAVeRa €9 m	Developing a decision-making tool accessing health and economic outcomes of vaccines on the reduction of AMR.

*This Phase 2a proof of concept trial is funded by the European & Developing Countries Clinical Trials Partnership and supported by the European Union.